RCG
PCRX icon

Ruggie Capital Group’s Pacira BioSciences PCRX Stock Holding History

Ruggie Capital Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-574
Closed -$19K – 209
2016
Q2 		$19K Buy
+574
New +$28.2K 0.02% 134

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ruggie Capital Group's PCRX Position: Q3 2016 in Review

Ruggie Capital Group sold out of Pacira BioSciences (PCRX) in Q3 2016, closing a stake of 574 shares — an estimated $19K sold.

Ruggie Capital Group first reported a position in PCRX in Q2 2016 and held it in 1 quarter. The position peaked at $19K in Q2 2016. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

  • Ruggie Capital Group reported no remaining Pacira BioSciences position as of Q3 2016 after selling out during the quarter.
  • Ruggie Capital Group sold 574 Pacira BioSciences shares in Q3 2016, an estimated $19K.
  • Ruggie Capital Group first reported a position in Pacira BioSciences in Q2 2016 and held it in 1 quarter.
  • Ruggie Capital Group's Pacira BioSciences position peaked at $19K in Q2 2016.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on Ruggie Capital Group's 13F filing for Q3 2016, filed 10 Nov 2016.